![]() ![]() The IGX Clone Browser, a powerful tool for exploring immune sequencing data, helps users to find what they are looking for, and was designed from scratch to provide a structured overview of all data, while allowing powerful and highly customizable searches. ![]() In immunomics, finding and selecting relevant clones is similar to finding the proverbial needle in a haystack, so it is essential that scientists have robust systems to explore, prioritize and select clones based on structured metadata and sequence information. Tags are native to the IGX user experience and offer an intuitive way to add metadata to repertoire sequences and organize them without endless layers of folders. Instead of using folders or groups to organize immune repertoire data, the IGX Platform offers an extensive, customizable tagging system that means data can be annotated at any level, providing limitless possibilities for organizing repertoire sequencing data in a meaningful way. Additionally, IGX can store, annotate and analyze paired receptor chains, and includes new search options tailored to the structure of paired receptor data, making it easier than ever to find and analyze single-cell data. The IGX Platform can be used with any sequencing technology, and can handle T and B cell receptor sequencing data derived from DNA or RNA, and prepared with any protocol. IGX requires no programming, so scientists can focus on research rather than coding (Fig. In addition, IGX allows researchers to integrate data with (meta)data from other domains, clinical as well as experimental. ![]() The IGX Platform is scalable by design, so users can browse hundreds of millions of sequences in internal and public databases with confidence and ease. IGX combines proprietary sequence-analysis algorithms, an intuitive user interface and several analysis apps to enable scientists in academic research centers and biopharmaceutical companies to accurately interpret large-scale repertoire data, speed up the extraction of biologically and clinically relevant information, and, most importantly, unlock insights that otherwise would remain obscured. To address this need, ENPICOM has brought together immunological expertise and innovative bioinformatics methods with robust and scalable software engineering to develop the IGX Platform, the first end-to-end solution on the market for the management, analysis and visualization of immune sequencing data. With the growing demand for personalized immunotherapies and accessible vaccines, especially against threats such as COVID-19, life scientists increasingly need new and efficient data management, analysis and integration tools to gain more insights into the adaptive immune system. The DNA/RNA data generated by immune repertoire sequencing is the most informative way to probe the immune system, but the millions of short sequencing reads it generates per sample-derived from highly variable receptor-encoding regions of the genome-are impossible to analyze with standard sequencing algorithms. One of the major challenges of decoding the immune system is characterizing an individual’s immune repertoire: the genetic code of the trillions of T and B cell receptors of the adaptive immune system. Last year, ENPICOM was listed as one of the top 15 most promising biotech start-ups in Europe by StartupCity, and this year was recognized as one of the 50 fastest-growing companies working in the field of data science in the Netherlands. ENPICOM, an innovative bioinformatics software engineering company, is dedicated to supporting immunological research in academic research centers, and improving and accelerating the discovery and development of novel vaccines and immunotherapies by biopharma companies, through ground-breaking products and customized solutions for immunomics data analysis.ĮNPICOM, based in the Netherlands, was founded in 2017, and today employs more than 25 scientists and software engineers. The immune system has always been central to understanding and treating infectious diseases and autoimmune conditions, and in recent decades has been recruited to fight cancers in immunotherapies from vaccines and bispecific antibodies, to a growing range of cell-based therapies. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |